PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.56%
Revenue growth under 50% of TSM's 21.19%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
145.36%
Gross profit growth above 1.5x TSM's 24.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
136.55%
EBIT growth above 1.5x TSM's 27.29%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
136.55%
Operating income growth above 1.5x TSM's 27.29%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
151.06%
Net income growth above 1.5x TSM's 24.99%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
151.85%
EPS growth above 1.5x TSM's 26.07%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
151.85%
Diluted EPS growth above 1.5x TSM's 26.07%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-2.09%
Share reduction while TSM is at 1.46%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
1.64%
Diluted share count expanding well above TSM's 1.46%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-46.88%
Negative OCF growth while TSM is at 90.24%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-340.52%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
500.98%
10Y revenue/share CAGR above 1.5x TSM's 276.54%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
64.54%
5Y revenue/share CAGR above 1.5x TSM's 27.48%. David Dodd would look for consistent product or market expansions fueling outperformance.
44.33%
3Y revenue/share CAGR above 1.5x TSM's 11.35%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
165.97%
OCF/share CAGR of 165.97% while TSM is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
544.73%
5Y OCF/share CAGR above 1.5x TSM's 18.70%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-52.03%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
278.30%
Similar net income/share CAGR to TSM's 280.54%. Walter Schloss would see parallel tailwinds or expansions for both firms.
765.55%
5Y net income/share CAGR above 1.5x TSM's 7.74%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-11.23%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
1541.41%
Equity/share CAGR of 1541.41% while TSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
119.46%
5Y equity/share CAGR above 1.5x TSM's 17.76%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
72.89%
Positive short-term equity growth while TSM is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.54%
Firm’s AR is declining while TSM shows 7.48%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
21.22%
Inventory growth well above TSM's 1.06%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-7.86%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-4.61%
We have a declining book value while TSM shows 5.15%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-0.26%
Our R&D shrinks while TSM invests at 21.69%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-2.22%
We cut SG&A while TSM invests at 14.72%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.